Extracellular vesicular microRNAs and cardiac hypertrophy
Cardiac hypertrophy is an adaptive response to pressure or volume overload such as hypertension and ischemic heart diseases. Sustained cardiac hypertrophy eventually leads to heart failure. The pathophysiological alterations of hypertrophy are complex, involving both cellular and molecular systems....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1444940/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850082605014188032 |
|---|---|
| author | Hai Hu Hai Hu Xiulian Wang Hui Yu Hui Yu Zhanli Wang |
| author_facet | Hai Hu Hai Hu Xiulian Wang Hui Yu Hui Yu Zhanli Wang |
| author_sort | Hai Hu |
| collection | DOAJ |
| description | Cardiac hypertrophy is an adaptive response to pressure or volume overload such as hypertension and ischemic heart diseases. Sustained cardiac hypertrophy eventually leads to heart failure. The pathophysiological alterations of hypertrophy are complex, involving both cellular and molecular systems. Understanding the molecular events that inhibit or repress cardiac hypertrophy may help identify novel therapeutic strategies. Increasing evidence has indicated that extracellular vesicle (EV)-derived microRNAs (miRNAs) play a significant role in the development and progression of cardiac hypertrophy. In this review, we briefly review recent advancements in EV research, especially on biogenesis, cargoes and its role in cardiac hypertrophy. We then describe the latest findings regarding EV-derived miRNAs, highlighting their functions and regulatory mechanisms in cardiac hypertrophy. Finally, the potential role of EV-derived miRNAs as targets in the diagnosis and treatment of cardiac hypertrophy will be discussed. |
| format | Article |
| id | doaj-art-dfab15af0c794dd8970e1afff153b9ee |
| institution | DOAJ |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-dfab15af0c794dd8970e1afff153b9ee2025-08-20T02:44:29ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-01-011510.3389/fendo.2024.14449401444940Extracellular vesicular microRNAs and cardiac hypertrophyHai Hu0Hai Hu1Xiulian Wang2Hui Yu3Hui Yu4Zhanli Wang5Inner Mongolia Key Laboratory of Disease-Related Biomarkers, The Second Affiliated Hospital, Baotou Medical College, Baotou, ChinaSchool of Basic Medicine, Baotou Medical College, Baotou, ChinaInner Mongolia Key Laboratory of Disease-Related Biomarkers, The Second Affiliated Hospital, Baotou Medical College, Baotou, ChinaInner Mongolia Key Laboratory of Disease-Related Biomarkers, The Second Affiliated Hospital, Baotou Medical College, Baotou, ChinaSchool of Basic Medicine, Baotou Medical College, Baotou, ChinaInner Mongolia Key Laboratory of Disease-Related Biomarkers, The Second Affiliated Hospital, Baotou Medical College, Baotou, ChinaCardiac hypertrophy is an adaptive response to pressure or volume overload such as hypertension and ischemic heart diseases. Sustained cardiac hypertrophy eventually leads to heart failure. The pathophysiological alterations of hypertrophy are complex, involving both cellular and molecular systems. Understanding the molecular events that inhibit or repress cardiac hypertrophy may help identify novel therapeutic strategies. Increasing evidence has indicated that extracellular vesicle (EV)-derived microRNAs (miRNAs) play a significant role in the development and progression of cardiac hypertrophy. In this review, we briefly review recent advancements in EV research, especially on biogenesis, cargoes and its role in cardiac hypertrophy. We then describe the latest findings regarding EV-derived miRNAs, highlighting their functions and regulatory mechanisms in cardiac hypertrophy. Finally, the potential role of EV-derived miRNAs as targets in the diagnosis and treatment of cardiac hypertrophy will be discussed.https://www.frontiersin.org/articles/10.3389/fendo.2024.1444940/fullcardiac hypertrophyextracellular vesiclemicroRNAinflammationregulatory mechanism |
| spellingShingle | Hai Hu Hai Hu Xiulian Wang Hui Yu Hui Yu Zhanli Wang Extracellular vesicular microRNAs and cardiac hypertrophy Frontiers in Endocrinology cardiac hypertrophy extracellular vesicle microRNA inflammation regulatory mechanism |
| title | Extracellular vesicular microRNAs and cardiac hypertrophy |
| title_full | Extracellular vesicular microRNAs and cardiac hypertrophy |
| title_fullStr | Extracellular vesicular microRNAs and cardiac hypertrophy |
| title_full_unstemmed | Extracellular vesicular microRNAs and cardiac hypertrophy |
| title_short | Extracellular vesicular microRNAs and cardiac hypertrophy |
| title_sort | extracellular vesicular micrornas and cardiac hypertrophy |
| topic | cardiac hypertrophy extracellular vesicle microRNA inflammation regulatory mechanism |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1444940/full |
| work_keys_str_mv | AT haihu extracellularvesicularmicrornasandcardiachypertrophy AT haihu extracellularvesicularmicrornasandcardiachypertrophy AT xiulianwang extracellularvesicularmicrornasandcardiachypertrophy AT huiyu extracellularvesicularmicrornasandcardiachypertrophy AT huiyu extracellularvesicularmicrornasandcardiachypertrophy AT zhanliwang extracellularvesicularmicrornasandcardiachypertrophy |